Company Overview and News

 
RESULTS FOR THE FULL YEAR ENDED 31 DECEMBER 2015

2016-02-19 londonstockexchange
·     Net debt of £374m (FY 2014: £62m), with cash flow generation offset by the acquisition of Clondalkin Specialist Packaging Division ("SPD") and higher dividends.

 
Abric down on plan for cash return, delisting

2016-01-19 thestar.com.my
KUALA LUMPUR : Shares in Abric Bhd fell on muted response by investors following the company’s announcement of a proposed cash distribution of 43 sen to entitled shareholders and a subsequent delisting from Bursa Malaysia.

 
Abric shares fall on capital repayment and delisting plans

2016-01-19 thestar.com.my
KUALA LUMPUR : Shares of Abric Bhd fell today after the PN16-classifed company announced a proposed cash distribution of 43 sen to entitled shareholders and a subsequent delisting from Bursa Malaysia.

 
Abric falls 2.94% on plan to exit Bursa Main Market

2016-01-19 themalaysianinsider
Shares of practice Note 16 company Abric Bhd fell 2.94% this morning after it proposed a cash distribution of 43 sen per ordinary share, and to exit Bursa…

 
KLCI opens lower, set to remain subdued

2016-01-19 themalaysianinsider
The FBM KLCI opened lower this morning and looked set to trade subdued in line with ite regional peers on still tepid investor sentiment. At 9am, the FBM…

 
Abric falls 2.94% on plan to exit Bursa Main Market

2016-01-19 theedgemarkets
KUALA LUMPUR (Jan 19): Shares of practice Note 16 company Abric Bhd fell 2.94% this morning after it proposed a cash distribution of 43 sen per ordinary share, and to exit Bursa Malaysia's Main Market. At 9.05am, Abric lost 1.5 sen to 49.5 sen with 128,000 shares traded. In a bourse filing on Monday, Abric said the cash distribution is to be implemented via a capital reduction and repayment exercise, and a special cash dividend, the ratio of which is yet to be fixed at this juncture.

 
Breakfast briefing: Tuesday, January 19

2016-01-19 thestar.com.my
Breakfast briefing: Tuesday, January 19

 
KLCI opens lower, set to remain subdued

2016-01-19 theedgemarkets
KUALA LUMPUR (Jan 19): The FBM KLCI opened lower this morning and looked set to trade subdued in line with ite regional peers on still tepid investor sentiment. At 9am, the FBM KLCI shed 0.27 points to 1,622.37. The early decliners included Public Bank Bhd, Petronas Chemicals Group Bhd, Pharmaniaga Holdings Bhd, Teck Seng (Malaysia) Bhd, C.I. Holdings Bhd, Pavilion REIT, Only World Group Holdings Bhd, MMC Corporation Bhd, IQ Group Bhd and Abric Bhd.

 
KLCI to consolidate, hover around 1,600-point level

2016-01-19 themalaysianinsider
The FBM KLCI is expected to consolidate further today and hover around the psychologically crucial level of 1,600 points in line with the overnight fall…

 
KLCI to consolidate, hover around 1,600-point level

2016-01-18 theedgemarkets
KUALA LUMPUR (Jan 19): The FBM KLCI is expected to consolidate further today and hover around the psychologically crucial level of 1,600 points in line with the overnight fall at most global markets. European shares fell on Monday, following Asia lower and led by banks after the European Central Bank said it would quiz euro zone lenders about high levels of bad loans, while oil prices tumbled on the prospect of more supply from Iran, according to Reuters.

 
DNeX, CIMB Group, EKA Noodles, Ranhill, MBSB, DRB-Hicom, Hap Seng, OWG, Abric, Boustead, Media Prima, CAB Cakaran and Axis REIT

2016-01-18 theedgemarkets
KUALA LUMPUR (Jan 18): Based on corporate announcements and news flows today, companies that may be in focus tomorrow (Tuesday Jan 19) could include: DNeX, CIMB Group, EKA Noodles, Ranhill, MBSB, DRB-Hicom, Hap Seng, OWG, Abric, Boustead, Media Prima, CAB Cakaran and Axis REIT. Dagang NeXchange Bhd (DNeX) is tapping into the Asian renewable energy market via a memorandum of understanding (MoU) it entered into with three companies.

 
Abric plans cash distribution of 43 sen

2016-01-18 thestar.com.my
KUALA LUMPUR: Cash rich Abric Bhd plans to distribute 43 sen a share totaling RM63.90mil to its shareholders under a corporate exercise which will lead to its delisting from Bursa Malaysia Securities.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...